Regenerx Biopharmaceuticals Financials
This page shows Regenerx Biopharmaceuticals (RGRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Regenerx Biopharmaceuticals passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Regenerx Biopharmaceuticals generates $0.54 in operating cash flow (-$941K OCF vs -$1.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Regenerx Biopharmaceuticals earns $-4.3 in operating income for every $1 of interest expense (-$1.4M vs $326K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Regenerx Biopharmaceuticals generated $77K in revenue in fiscal year 2022. This represents an increase of 0.0% from the prior year.
Regenerx Biopharmaceuticals reported -$1.7M in net income in fiscal year 2022. This represents a decrease of 8.1% from the prior year.
Regenerx Biopharmaceuticals earned $-0.01 per diluted share (EPS) in fiscal year 2022. This represents an increase of 0.0% from the prior year.
Regenerx Biopharmaceuticals held $291K in cash against $0 in long-term debt as of fiscal year 2022.
Regenerx Biopharmaceuticals had 144M shares outstanding in fiscal year 2022. This represents an increase of 0.0% from the prior year.
Regenerx Biopharmaceuticals's operating margin was -1826.4% in fiscal year 2022, reflecting core business profitability. This is down 95.7 percentage points from the prior year.
Regenerx Biopharmaceuticals's net profit margin was -2250.4% in fiscal year 2022, showing the share of revenue converted to profit. This is down 169.0 percentage points from the prior year.
Regenerx Biopharmaceuticals invested $0 in research and development in fiscal year 2022. This represents a decrease of 100.0% from the prior year.
RGRX Income Statement
| Metric | Q1'23 | Q1'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $35K | $0 | $0 | $0 | $0 | $0-100.0% | $6K+1062.8% | $487 |
| SG&A Expenses | $324K-1.2% | $328K+8.0% | $304K-37.3% | $484K+33.3% | $363K-6.1% | $387K-7.4% | $418K+51.2% | $276K |
| Operating Income | -$305K+1.3% | -$309K-8.6% | -$284K+38.8% | -$465K-35.2% | -$344K+6.5% | -$368K+9.0% | -$404K-56.9% | -$257K |
| Interest Expense | $80K-2.2% | $82K0.0% | $82K+1.1% | $81K+1.1% | $80K-2.2% | $82K+0.9% | $81K+0.2% | $81K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$385K+1.5% | -$391K-6.7% | -$367K+32.9% | -$546K-28.7% | -$424K+5.7% | -$450K-4.6% | -$430K-26.9% | -$339K |
| EPS (Diluted) | $0.00+100.0% | $-0.01 | $0.00 | $0.00 | $0.00+100.0% | $-0.01 | $0.00 | $0.00 |
RGRX Balance Sheet
| Metric | Q1'23 | Q1'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $187K-51.1% | $382K-34.2% | $581K-21.0% | $736K-23.4% | $961K-25.2% | $1.3M-19.4% | $1.6M-24.5% | $2.1M |
| Current Assets | $123K-59.8% | $307K-38.5% | $499K-31.2% | $726K-22.7% | $939K-25.0% | $1.3M-19.2% | $1.5M-24.6% | $2.1M |
| Cash & Equivalents | $102K-65.1% | $291K-39.2% | $478K-32.3% | $707K-23.6% | $925K-24.9% | $1.2M-19.2% | $1.5M-24.8% | $2.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | $214K | N/A | N/A | N/A | $11K | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.9M+2.7% | $3.8M+2.8% | $3.7M+3.5% | $3.6M+2.0% | $3.5M+0.3% | $3.5M+1.5% | $3.5M-5.5% | $3.7M |
| Current Liabilities | $1.8M+225.0% | $554K+16.3% | $476K+10.0% | $433K+7.4% | $403K-6.3% | $430K+3.0% | $418K-34.0% | $633K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.7M-8.7% | -$3.4M-9.7% | -$3.1M-9.8% | -$2.9M-11.5% | -$2.6M-15.1% | -$2.2M-19.3% | -$1.9M-20.3% | -$1.6M |
| Retained Earnings | -$112.6M-0.3% | -$112.2M-0.3% | -$111.8M-0.3% | -$111.5M-0.5% | -$110.9M-0.4% | -$110.5M-0.4% | -$110.0M-0.4% | -$109.6M |
RGRX Cash Flow Statement
| Metric | Q1'23 | Q1'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$189K-1.0% | -$188K+17.8% | -$228K-4.4% | -$219K+28.6% | -$306K-5.0% | -$292K+32.2% | -$431K-1586.3% | -$26K |
| Capital Expenditures | N/A | $0 | $0 | $0-100.0% | $1K-57.5% | $3K+108.2% | $1K | N/A |
| Free Cash Flow | N/A | -$292K+46.7% | -$548K+66.7% | -$1.6M-28.4% | -$1.3M-12.4% | -$1.1M+29.6% | -$1.6M | N/A |
| Investing Cash Flow | N/A | $0 | $0 | $0+100.0% | -$1K+57.5% | -$3K-108.2% | -$1K | N/A |
| Financing Cash Flow | $0 | $0-100.0% | $159K | $0 | $0 | $0+100.0% | -$72K-103.9% | $1.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RGRX Financial Ratios
| Metric | Q1'23 | Q1'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1588.9%+20.6pp | -1609.5%-127.1pp | -1482.3%+939.8pp | -2422.2%-630.5pp | -1791.7%+124.0pp | -1915.7%+189.8pp | -2105.5%-764.0pp | -1341.5% |
| Net Margin | -2007.3%+29.8pp | -2037.1%-127.3pp | -1909.9%+935.1pp | -2845.0%-635.2pp | -2209.7%+133.2pp | -2342.9%-103.0pp | -2239.9%-475.4pp | -1764.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -206.2%-103.9pp | -102.3%-39.2pp | -63.1%+11.1pp | -74.2%-30.1pp | -44.1%-9.2pp | -35.0%-8.0pp | -27.0%-10.9pp | -16.0% |
| Current Ratio | 0.07-0.5 | 0.55-0.5 | 1.05-0.6 | 1.68-0.7 | 2.33-0.6 | 2.91-0.8 | 3.71+0.5 | 3.25 |
| Debt-to-Equity | -1.05+0.1 | -1.11+0.1 | -1.19+0.1 | -1.26+0.1 | -1.37+0.2 | -1.58+0.3 | -1.85+0.5 | -2.36 |
| FCF Margin | N/A | -2297.2%+2012.5pp | -4309.6% | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.55), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Regenerx Biopharmaceuticals's annual revenue?
Regenerx Biopharmaceuticals (RGRX) reported $77K in total revenue for fiscal year 2022. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regenerx Biopharmaceuticals's revenue growing?
Regenerx Biopharmaceuticals (RGRX) revenue grew by 0% year-over-year, from $77K to $77K in fiscal year 2022.
Is Regenerx Biopharmaceuticals profitable?
No, Regenerx Biopharmaceuticals (RGRX) reported a net income of -$1.7M in fiscal year 2022, with a net profit margin of -2250.4%.
What is Regenerx Biopharmaceuticals's earnings per share (EPS)?
Regenerx Biopharmaceuticals (RGRX) reported diluted earnings per share of $-0.01 for fiscal year 2022. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Regenerx Biopharmaceuticals's operating margin?
Regenerx Biopharmaceuticals (RGRX) had an operating margin of -1826.4% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.
What is Regenerx Biopharmaceuticals's net profit margin?
Regenerx Biopharmaceuticals (RGRX) had a net profit margin of -2250.4% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.
What is Regenerx Biopharmaceuticals's operating cash flow?
Regenerx Biopharmaceuticals (RGRX) generated -$941K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Regenerx Biopharmaceuticals's total assets?
Regenerx Biopharmaceuticals (RGRX) had $382K in total assets as of fiscal year 2022, including both current and long-term assets.
How many shares does Regenerx Biopharmaceuticals have outstanding?
Regenerx Biopharmaceuticals (RGRX) had 144M shares outstanding as of fiscal year 2022.
What is Regenerx Biopharmaceuticals's current ratio?
Regenerx Biopharmaceuticals (RGRX) had a current ratio of 0.55 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Regenerx Biopharmaceuticals's debt-to-equity ratio?
Regenerx Biopharmaceuticals (RGRX) had a debt-to-equity ratio of -1.11 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regenerx Biopharmaceuticals's return on assets (ROA)?
Regenerx Biopharmaceuticals (RGRX) had a return on assets of -452.0% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Regenerx Biopharmaceuticals's cash runway?
Based on fiscal year 2022 data, Regenerx Biopharmaceuticals (RGRX) had $291K in cash against an annual operating cash burn of $941K. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Regenerx Biopharmaceuticals's debt-to-equity ratio negative or unusual?
Regenerx Biopharmaceuticals (RGRX) has negative shareholder equity of -$3.4M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regenerx Biopharmaceuticals's Piotroski F-Score?
Regenerx Biopharmaceuticals (RGRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regenerx Biopharmaceuticals's earnings high quality?
Regenerx Biopharmaceuticals (RGRX) has an earnings quality ratio of 0.54x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regenerx Biopharmaceuticals cover its interest payments?
Regenerx Biopharmaceuticals (RGRX) has an interest coverage ratio of -4.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.